207 related articles for article (PubMed ID: 22973954)
1. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.
Voortman J; Harada T; Chang RP; Killian JK; Suuriniemi M; Smith WI; Meltzer PS; Lucchi M; Wang Y; Giaccone G
Curr Pharm Des; 2013; 19(5):833-40. PubMed ID: 22973954
[TBL] [Abstract][Full Text] [Related]
2. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
3. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
[TBL] [Abstract][Full Text] [Related]
4. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
Jagadeeswaran R; Jagadeeswaran S; Bindokas VP; Salgia R
Am J Physiol Lung Cell Mol Physiol; 2007 Jun; 292(6):L1488-94. PubMed ID: 17322284
[TBL] [Abstract][Full Text] [Related]
5. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
Kanteti R; Nallasura V; Loganathan S; Tretiakova M; Kroll T; Krishnaswamy S; Faoro L; Cagle P; Husain AN; Vokes EE; Lang D; Salgia R
Lab Invest; 2009 Mar; 89(3):301-14. PubMed ID: 19139719
[TBL] [Abstract][Full Text] [Related]
6. c-Met is a potentially new therapeutic target for treatment of human melanoma.
Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
[TBL] [Abstract][Full Text] [Related]
7. Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients.
Bordi P; Tiseo M; Barbieri F; Bavieri M; Sartori G; Marchetti A; Buttitta F; Bortesi B; Ambrosini-Spaltro A; Gnetti L; Silini EM; Ardizzoni A; Rossi G
Lung Cancer; 2014 Dec; 86(3):324-8. PubMed ID: 25453846
[TBL] [Abstract][Full Text] [Related]
8. Single-nucleotide polymorphism rs41736 located in MET was significantly associated with prognosis of small cell lung cancer patients.
Cao X; Hong X; Jia X; Zhang L; Chen G
Med Oncol; 2014 Dec; 31(12):333. PubMed ID: 25416047
[TBL] [Abstract][Full Text] [Related]
9. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
Rolle CE; Kanteti R; Surati M; Nandi S; Dhanasingh I; Yala S; Tretiakova M; Arif Q; Hembrough T; Brand TM; Wheeler DL; Husain AN; Vokes EE; Bharti A; Salgia R
Mol Cancer Ther; 2014 Mar; 13(3):576-84. PubMed ID: 24327519
[TBL] [Abstract][Full Text] [Related]
10. Ethnic differences and functional analysis of MET mutations in lung cancer.
Krishnaswamy S; Kanteti R; Duke-Cohan JS; Loganathan S; Liu W; Ma PC; Sattler M; Singleton PA; Ramnath N; Innocenti F; Nicolae DL; Ouyang Z; Liang J; Minna J; Kozloff MF; Ferguson MK; Natarajan V; Wang YC; Garcia JG; Vokes EE; Salgia R
Clin Cancer Res; 2009 Sep; 15(18):5714-23. PubMed ID: 19723643
[TBL] [Abstract][Full Text] [Related]
11. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells.
Kalari S; Jung M; Kernstine KH; Takahashi T; Pfeifer GP
Oncogene; 2013 Jul; 32(30):3559-68. PubMed ID: 22907430
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells.
Wang ZX; Lu BB; Yang JS; Wang KM; De W
J Surg Res; 2011 Nov; 171(1):127-35. PubMed ID: 20338593
[TBL] [Abstract][Full Text] [Related]
13. RET mutation and expression in small-cell lung cancer.
Dabir S; Babakoohi S; Kluge A; Morrow JJ; Kresak A; Yang M; MacPherson D; Wildey G; Dowlati A
J Thorac Oncol; 2014 Sep; 9(9):1316-23. PubMed ID: 25122427
[TBL] [Abstract][Full Text] [Related]
14. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.
Zimmer Y; Vaseva AV; Medová M; Streit B; Blank-Liss W; Greiner RH; Schiering N; Aebersold DM
Cancer Lett; 2010 Mar; 289(2):228-36. PubMed ID: 19783361
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.
Kenessey I; Keszthelyi M; Krámer Z; Berta J; Adám A; Dobos J; Mildner M; Flachner B; Cseh S; Barna G; Szokol B; Orfi L; Kéri G; Döme B; Klepetko W; Tímár J; Tóvári J
Curr Cancer Drug Targets; 2010 May; 10(3):332-42. PubMed ID: 20370683
[TBL] [Abstract][Full Text] [Related]
18. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines.
Arriola E; Cañadas I; Arumí-Uría M; Dómine M; Lopez-Vilariño JA; Arpí O; Salido M; Menéndez S; Grande E; Hirsch FR; Serrano S; Bellosillo B; Rojo F; Rovira A; Albanell J
Br J Cancer; 2011 Sep; 105(6):814-23. PubMed ID: 21847116
[TBL] [Abstract][Full Text] [Related]
19. c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer.
de Aguirre I; Salvatierra A; Font A; Mate JL; Perez M; Botia M; Taron M; Rosell R
Transl Oncogenomics; 2006; 1():11-8. PubMed ID: 23662036
[TBL] [Abstract][Full Text] [Related]
20. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
Bellon SF; Kaplan-Lefko P; Yang Y; Zhang Y; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O'Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I
J Biol Chem; 2008 Feb; 283(5):2675-83. PubMed ID: 18055465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
